Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06305728
Status:
RECRUITING
Last Update Posted:
2024-03-12
First Post:
2024-03-05
Brief Title:
Hyperpolarized C Pyruvate Magnetic Resonance Imaging and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients with Intraductal Papillary Mucinous Neoplasms
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Immuno-Positron Emission Tomography Hyperpolarized C Pyruvate Magnetic Resonance Imaging and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients with Intraductal Papillary Mucinous Neoplasms
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinomaPDAC early to avoid the invasive procedure of surgery The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early In this study researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts
The ImmunoPET scan immune-positron emission tomography scan with the imaging agent 89Zr-DFO-HuMab-5B1
The HP MRI scan hyperpolarized pyruvate magnetic resonance imaging scan
The ImmunoPET scan immune-positron emission tomography scan with the imaging agent 89Zr-DFO-HuMab-5B1
The HP MRI scan hyperpolarized pyruvate magnetic resonance imaging scan
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None